Low-Dose Aspirin's Role in Nonalcoholic Fatty Liver Disease

1. Low-Dose Aspirin's Impact: In a 6-month study, daily intake of low-dose aspirin (81mg) demonstrated a substantial 10.3% reduction in liver fat content in patients with Metabolic-Associated Steatotic Liver Disease (MASLD) compared to a placebo.

2. Secondary Endpoints Triumph: Aspirin outperformed the placebo in secondary endpoints, showing significant improvements in MRI Proton-Density Fat Fraction (MRI-PDFF), indicating a reduction in hepatic fat. Additionally, it led to notable decreases in liver transaminase levels and liver stiffness.

3. Safety and Tolerance: The study affirmed the safety and tolerability of low-dose aspirin, with only one related adverse event (heartburn) leading to discontinuation. Importantly, no serious bleeding events were reported in either study arm.

4. Implications for Future Trials: Researchers suggest considering aspirin use stratification in future MASLD trials, highlighting its potential integration into treatment protocols. This underlines the need for more extensive and longer-term clinical trials to assess its efficacy further.

5. Therapeutic Promise for MASLD: The study's findings offer a promising avenue for treating MASLD without cirrhosis, providing hope for patients grappling with the condition. The results underscore the urgency of continued exploration into aspirin's role in managing liver diseases.

Metabolic-associated steatotic liver disease (NAFLD) is a condition characterized by the accumulation of fat in the liver due to metabolic dysfunction. It is often associated with factors such as obesity, insulin resistance, and other metabolic abnormalities. MAFLD can progress from simple steatosis (fatty liver) to more severe conditions like non-alcoholic steatohepatitis (NASH) and liver fibrosis.

Key points about MAFLD include:

1. Metabolic Dysfunction: MAFLD is closely linked to metabolic factors, including obesity, insulin resistance, and metabolic syndrome.

2. Symptoms: It may manifest with symptoms such as confusion, sleepiness, and slurred speech, known as hepatic encephalopathy, as well as complications like hypersplenism (overactive spleen).

3. Treatment: Management involves addressing underlying metabolic issues, lifestyle modifications, and sometimes medication. Statin therapy has shown promise in reducing steatosis grades and NAS scores in some cases

4. Post-Transplant Risk: Post-liver transplant, factors like post-transplant diabetes and obesity can contribute to post-transplant MAFLD

Latest Research

In a groundbreaking study presented at The Liver Meeting 2023 by the American Association for the Study of Liver Diseases (AASLD), researchers from Massachusetts General Hospital in Boston unveiled a promising development in the treatment of Metabolic-Associated Steatotic Liver Disease (MASLD). The study, led by Dr Robert M. Wilechansky, explored the effects of daily low-dose aspirin on patients with MASLD without cirrhosis, revealing significant reductions in liver fat content over a span of 6 months compared to those who took a placebo.

The Study's Rationale

With MASLD lacking approved treatments by the US Food and Drug Administration, the researchers turned their attention to aspirin, known for its anti-inflammatory properties. Aspirin's potential as a treatment for MASLD stems from preclinical studies showcasing its anti-inflammatory and antitumor effects in the liver. Observational studies also hinted at a reduction in hepatic steatosis and fibrosis progression in MASLD patients using aspirin.

Methodology and Key Findings

The researchers enrolled 80 adults with MASLD without cirrhosis and randomly assigned them to receive either aspirin (81 mg once daily) or a placebo for 6 months. The primary endpoint, the absolute change in hepatic fat fraction (HFF), showed a remarkable decline of 6.1% in the aspirin group compared to a 4.2% increase in the placebo group, resulting in a notable 10.3% difference favoring aspirin (P = .009).

Secondary Endpoints

1. MRI Proton-Density Fat Fraction (MRI-PDFF)

Aspirin demonstrated superiority over placebo in both the absolute (-2.9% vs. placebo, P = .018) and relative (-24.8% vs. placebo, P = .009) change in hepatic fat measured by MRI-PDFF.

2. Liver Transaminase Levels and Liver Stiffness

Patients taking aspirin experienced significantly greater reductions in liver transaminase levels and liver stiffness as measured by vibration-controlled transient elastography (VCTE).

Safety and Tolerability

The study highlighted the safety and tolerability of low-dose aspirin, with only one aspirin-related adverse event (heartburn) leading to discontinuation. Notably, there were no serious bleeding events in either study arm.

Implications and Future Directions

While the results are promising, Dr. Wilechansky emphasized the need for larger, longer-term clinical trials to assess aspirin's efficacy in improving histology and preventing adverse outcomes in MASLD. The study's success prompts considerations for aspirin use stratification in future trials, opening avenues for potential integration into MASLD treatment protocols.

Conclusion

In conclusion, the study's findings present a compelling case for the therapeutic potential of low-dose aspirin in reducing liver fat, and inflammation markers, and improving overall liver health in MASLD patients without cirrhosis. As the medical community eagerly awaits further research, these results offer a glimmer of hope for those grappling with MASLD and underscore the urgency of continued exploration into aspirin's role in liver disease management.

References

Low-Dose Aspirin Reduces Liver Fat, Inflammation Markers - Medscape - Nov 16, 2023.

https://www.clinicaltrials.gov/study/NCT04031729?term=low-dose%20aspirin%20NAFLD&rank=1

Related

https://healthnewstrend.com/time-restricted-eating-and-its-influence-on-nonalcoholic-fatty-liver-disease

Medical Disclaimer

The information on this website is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.